Effects of high-fat diet and the anti-diabetic drug metformin on circulating GLP-1 and the relative number of intestinal L-cells

Diabetology and Metabolic Syndrome

Volumn 6, Issue 1, 2014, Pages

  Kappe, Camilla ^a,b   Zhang, Qimin ^a   Nyström, Thomas ^a   Sjöholm, Åke ^a,c,d  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Södertälje University   (Sweden)

^d UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Glucagon like peptide 1; Insulinotropic; L cell; Lipotoxicity; Metformin

Indexed keywords

FATTY ACID; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; METFORMIN; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FATTY ACID BLOOD LEVEL; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTESTINE CELL; L CELL LINE; LIPID DIET; NONHUMAN; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RODENT MODEL; TISSUE SECTION;

EID: 84904469202     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-6-70     Document Type: Article

References (18)

1. The role of gut hormones in glucose homeostasis. Drucker DJ, J Clin Invest 2007 117 24 32 10.1172/JCI30076 17200703
2. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ, Diabetes 2001 50 609 613 10.2337/diabetes.50.3. 609 11246881
3. Glucagon-like peptide 1(GLP-1) in biology and pathology. Meier JJ, Nauck MA, Diabetes Metab Res Rev 2005 21 91 117 10.1002/dmrr.538 15759282
4. A novel glucose-sensing mechanism contributing to glucagon-like peptide-1 secretion from the GLUTag cell line. Gribble FM, Williams L, Simpson AK, Reimann F, Diabetes 2003 52 1147 1154 10.2337/diabetes.52.5.1147 12716745
5. Nutritional regulation of glucagon-like peptide-1 secretion. Tolhurst G, Reimann F, Gribble FM, J Physiol 2009 587 27 32 10.1113/jphysiol.2008.164012 19001044
6. Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. Kappe C, Patrone C, Holst JJ, Zhang Q, Sjoholm A, J Gastroenterol 2013 48 322 332 10.1007/s00535-012-0637-5 22850868
7. Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion. Beglinger S, Drewe J, Schirra J, Goke B, D'Amato M, Beglinger C, J Clin Endocrinol Metab 2010 95 879 886 10.1210/jc.2009-1062 19837920
8. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM, Diabetes 2012 61 364 371 10.2337/db11-1019 22190648
9. Molecular mechanisms underlying nutrient detection by incretin-secreting cells. Reimann F, Int Dairy J 2010 20 236 242 10.1016/j.idairyj.2009.11.014 20204054
10. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE, Proc Natl Acad Sci U S A 2003 100 3077 3082 10.1073/pnas.0630588100 12629214
11. Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Cnop M, Hannaert JC, Hoorens A, Eizirik DL, Pipeleers DG, Diabetes 2001 50 1771 1777 10.2337/diabetes.50.8.1771 11473037
12. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Muscelli E, Mari A, Casolaro A, Camastra S, Seghieri G, Gastaldelli A, Holst JJ, Ferrannini E, Diabetes 2008 57 1340 1348 10.2337/db07-1315 18162504
13. Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. Kappe C, Holst JJ, Zhang Q, Sjoholm A, Biochem Biophys Res Commun 2012 427 91 95 10.1016/j.bbrc.2012.09.010 22982676
14. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Messeri G, Rotella CM, Diabetes Care 2001 24 489 494 10.2337/diacare.24.3.489 11289473
15. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A, West MJ, APMIS 1988 96 379 394 10.1111/j.1699-0463.1988.tb05320.x 3288247
16. Reducing insulin resistance with metformin: the evidence today. Giannarelli R, Aragona M, Coppelli A, Del Prato S, Diabetes Metab 2003 29 6S28 6S35 10.1016/S1262-3636(07)70079-4 14502098
17. Metformin reduces body weight gain and improves glucose intolerance in high-fat diet-fed C57BL/6 J mice. Matsui Y, Hirasawa Y, Sugiura T, Toyoshi T, Kyuki K, Ito M, Biol Pharm Bull 2010 33 963 970 10.1248/bpb.33.963 20522960
18. Upregulated insulin secretion in insulin-resistant mice: evidence of increased islet GLP1 receptor levels and GPR119-activated GLP1 secretion. Ahlkvist L, Brown K, Ahren B, Endocr Connect 2013 2 69 78 10.1530/EC-12-0079 23781322